EA201270135A1 - T-клеточные рецепторы - Google Patents

T-клеточные рецепторы

Info

Publication number
EA201270135A1
EA201270135A1 EA201270135A EA201270135A EA201270135A1 EA 201270135 A1 EA201270135 A1 EA 201270135A1 EA 201270135 A EA201270135 A EA 201270135A EA 201270135 A EA201270135 A EA 201270135A EA 201270135 A1 EA201270135 A1 EA 201270135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tcr
seq
variable domain
alpha
beta
Prior art date
Application number
EA201270135A
Other languages
English (en)
Other versions
EA026918B1 (ru
Inventor
Бент Карстен Якобсен
Наоми Харвуд
Натаниел Росс Лидди
Original Assignee
Иммунокор Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммунокор Лтд. filed Critical Иммунокор Лтд.
Publication of EA201270135A1 publication Critical patent/EA201270135A1/ru
Publication of EA026918B1 publication Critical patent/EA026918B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Т-клеточный рецептор (TCR), обладающий связывающей способностью к gp100 YLEPGPVTA пептид-HLA-А2 комплексу и содержащий альфа вариабельный домен TCR и/или бета вариабельный домен TCR, характеризующийся тем, что: (i) указанный TCR является мутированным по сравнению с TCR, имеющим внеклеточные последовательности альфа- и бета-цепи SEQ ID Nos:2 и 3, в его вариабельном домене альфа-цепи с 1 по 109 аминокислот SEQ ID No:2 и/или вариабельном домене бета-цепи с 1 по 112 аминокислот SEQ ID No:3; и (ii) указанный вариабельный домен альфа-цепи имеет, по меньшей мере, 90% идентичности последовательности к аминокислотной последовательности с 1 по 112 SEQ ID No:3; и (iii) указанный TCR обладает связывающей способностью к и/или фиксированным периодом полувыведения для YLEPGPVTA-HLA-A2 комплекса, по меньшей мере, в два раза больше, чем для эталонного TCR, указанный эталонный TCR имеет внеклеточную последовательность альфа-цепи SEQ ID No:45 и внеклеточную последовательность бета-цепи SEQ ID No:46. Применение таких TCR в адоптивной терапии и слияния таких TCRs с терапевтическими агентами также описано.
EA201270135A 2009-07-03 2010-07-01 T-клеточные рецепторы EA026918B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0911566.8A GB0911566D0 (en) 2009-07-03 2009-07-03 T cell receptors
PCT/GB2010/001277 WO2011001152A1 (en) 2009-07-03 2010-07-01 T cell receptors

Publications (2)

Publication Number Publication Date
EA201270135A1 true EA201270135A1 (ru) 2012-09-28
EA026918B1 EA026918B1 (ru) 2017-05-31

Family

ID=41008692

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270135A EA026918B1 (ru) 2009-07-03 2010-07-01 T-клеточные рецепторы

Country Status (18)

Country Link
US (2) US8519100B2 (ru)
EP (1) EP2448963B1 (ru)
JP (2) JP5872464B2 (ru)
CN (3) CN102574906A (ru)
AU (1) AU2010267758C1 (ru)
BR (1) BR112012000107A2 (ru)
CA (1) CA2766505C (ru)
DK (1) DK2448963T3 (ru)
EA (1) EA026918B1 (ru)
ES (1) ES2498190T3 (ru)
FR (1) FR22C1046I1 (ru)
GB (1) GB0911566D0 (ru)
HK (1) HK1169422A1 (ru)
MX (1) MX2012000155A (ru)
NL (1) NL301193I2 (ru)
PT (1) PT2448963E (ru)
WO (1) WO2011001152A1 (ru)
ZA (1) ZA201109522B (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EP2760892A1 (en) * 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
CN110511278A (zh) 2012-05-07 2019-11-29 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
SI2951202T1 (sl) 2013-01-29 2020-08-31 Max Delbrueck Centrum fuer Molekulare Medizin (MDC) Berlin-Buch Vezavne molekule z visoko avidnostjo, ki prepoznajo mage-A1
NZ715815A (en) * 2013-06-26 2017-02-24 Guangzhou Xiangxue Pharmaceutical Co Ltd High-stability t-cell receptor and preparation method and application thereof
WO2015077615A1 (en) * 2013-11-22 2015-05-28 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human t cell receptors
DE202014002754U1 (de) 2014-03-31 2015-07-03 Christian Piotrowski Ausgusssystem mit Pullring der mit der Folie verbunden ist.
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
CN106459176B (zh) * 2014-06-18 2018-07-06 广东香雪精准医疗技术有限公司 高亲和力hcv t细胞受体
CA2955984A1 (en) * 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
CA2956545A1 (en) * 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
AU2015338984A1 (en) * 2014-10-31 2017-04-27 The Trustees Of The University Of Pennsylvania Methods and compositions for modified T cells
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
NZ737400A (en) * 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
TWI826891B (zh) 2016-03-16 2023-12-21 德商英麥提克生物技術股份有限公司 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
GB201604953D0 (en) * 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
US11015093B2 (en) 2016-03-28 2021-05-25 Dow Global Technologies Llc Two-component solventless adhesive compositions and methods of making same
JP2019517499A (ja) * 2016-06-02 2019-06-24 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ−抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
HRP20211677T1 (hr) 2016-08-17 2022-02-18 Immatics Biotechnologies Gmbh T-stanični receptori i imunološka terapija koja koristi iste
WO2018050902A2 (en) * 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
SG11201908527SA (en) 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
CA3075376A1 (en) 2017-09-22 2019-03-28 Wuxi Biologics Ireland Limited. Bispecific cd3/cd19 polypeptide complexes
JP2021500875A (ja) 2017-10-06 2021-01-14 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ キメラ抗原受容体
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
WO2020028595A2 (en) * 2018-07-31 2020-02-06 Janux Therapeutics, Inc. Inhibitory t cell receptor peptides and discovery methods
CA3126611A1 (en) * 2019-01-17 2020-07-23 Immunocore Limited Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
WO2020247867A2 (en) * 2019-06-06 2020-12-10 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
US20220281949A1 (en) * 2019-07-30 2022-09-08 University Health Network Mhc class ii molecules and methods of use thereof
CN111234004B (zh) * 2020-02-28 2023-03-28 陕西九州新药评价研究有限公司(西安新药评价研究中心) 识别wt1抗原短肽的t细胞受体及其应用
US20230190812A1 (en) * 2020-05-18 2023-06-22 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
CN114853879A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688747A (en) 1994-08-22 1997-11-18 Becton Dickinson And Company Water based lubricant solution
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
ID28040A (id) * 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
PL208712B1 (pl) * 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
DK1558643T3 (da) 2002-11-09 2009-09-07 Immunocore Ltd Cellereceptorpr sentation
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
CA2567349C (en) 2004-05-19 2012-11-27 Avidex Ltd Method of improving t cell receptors
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US20060045884A1 (en) * 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US20080274133A1 (en) * 2004-11-18 2008-11-06 Avidex Ltd. Soluble Bifunctional Proteins
US7612180B2 (en) * 2005-03-03 2009-11-03 Immunomedics, Inc. Humanized L243 antibodies
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
US8216565B2 (en) 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
PT2448963E (pt) 2014-09-01
EP2448963A1 (en) 2012-05-09
DK2448963T3 (da) 2014-08-25
HK1169422A1 (en) 2013-01-25
NL301193I2 (nl) 2022-11-24
CA2766505C (en) 2019-01-22
AU2010267758C1 (en) 2015-01-22
EA026918B1 (ru) 2017-05-31
JP2012531904A (ja) 2012-12-13
US20120225481A1 (en) 2012-09-06
CN107266560A (zh) 2017-10-20
ZA201109522B (en) 2013-05-29
JP2016039812A (ja) 2016-03-24
US20140099699A1 (en) 2014-04-10
CN104017067A (zh) 2014-09-03
CN102574906A (zh) 2012-07-11
NL301193I1 (ru) 2022-08-17
MX2012000155A (es) 2012-06-28
AU2010267758A1 (en) 2012-02-09
EP2448963B1 (en) 2014-06-04
AU2010267758B2 (en) 2014-09-04
ES2498190T3 (es) 2014-09-24
FR22C1046I1 (fr) 2022-10-14
US9068178B2 (en) 2015-06-30
JP6186412B2 (ja) 2017-08-23
BR112012000107A2 (pt) 2016-11-01
GB0911566D0 (en) 2009-08-12
US8519100B2 (en) 2013-08-27
WO2011001152A1 (en) 2011-01-06
JP5872464B2 (ja) 2016-03-01
CA2766505A1 (en) 2011-01-06
CN104017067B (zh) 2017-11-03

Similar Documents

Publication Publication Date Title
EA201270135A1 (ru) T-клеточные рецепторы
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
EP3024468B1 (en) T cell receptors
AR108427A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
HRP20170086T1 (hr) Bifunkcionalni polipeptidi
US20160199479A1 (en) T cell receptors
ATE417065T1 (de) Hochaffiner ny-eso-t-zellen-rezeptor
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
RU2017115932A (ru) T-клеточные рецепторы
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201390011A1 (ru) Т-клеточные рецепторы
NZ603623A (en) Tcr complex immunotherapeutics
MX2018013581A (es) Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii.
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
JP2017533698A5 (ru)
MX2012000316A (es) Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.
Picarda et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection
NZ592261A (en) Novel immunotherapy against neuronal and brain tumors
WO2012044999A3 (en) Reversible protein multimers, methods for their production and use
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
EA201270802A1 (ru) Димерные слитые белки vstm3 и связанные с ними композиции и способы
NZ585131A (en) Use melanocortins to treat insulin sensitivity
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
MD3430037T2 (ro) Celule T transfectate și receptori de celule T pentru utilizare în imunoterapie împotriva cancerelor
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM